Indinavir sulfate

Drugs of the Future

Volumn 21, Issue 6, 1996, Pages 600-609

  Mealy, N ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; PROTEINASE; PROTEINASE INHIBITOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SHORT SURVEY; SPECIES DIFFERENCE; VIRUS INHIBITION;

EID: 0029997719     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.06.361961     Document Type: Short Survey

References (59)

1. Verhoeven, T.R., Roberts, E.F., Senanayake, C.H., Ryan, K.M (Merck & Co., Inc.). Regiospecific processes to make cis-1-amino-2-alkanol from diol or halohydrin. US 5449830.
2. Askin, D., Eng, K.K., Rossen, K., Purick, R.M., Wells, K.M., Volante, R.P., Reider, P.J. Highly diastereoselective reaction of a chiral, non-racemic amide enolate with (S)-glycidyl tosylate. Synthesis of the orally active HIV-1 protease inhibitor L-735,524. Tetrahedron Lett 1994, 35: 673-6.
3. Maligres, P.E., Upadhyay, V., Rossen, K., Cianciosi, S.J., Purick, R.M., Eng, K.K., Reamer, R.A., Askin, D., Volante, R.P., Reider, P.J. Diastereoselective syn-epoxidation of 2-alkyl-4-enamides to epoxyamides: Synthesis of the Merck HIV-1 protease inhibitor epoxide intermediate. Tetrahedron Lett 1995, 36: 2195-8.
4. Vacca, J.P., Holloway, M.K., Dorsey, B.D., Hungate, R.W., Guare, J.R. (Merck & Co., Inc.). HIV protease inhibitors useful for the treatment of AIDS. EP 541168, JP 93279337, WO 9309096.
5. Askin, D., Reider, P., Rossen, K., Varsolona, R.J., Wells, K.M. (Merck & Co., Inc.). Process for making HIV protease inhibitors. WO 9502583.
6. Askin, D., Volante, R.P., Eng, K.K. (Merck & Co., Inc.). Process for making HIV protease inhibitors. WO 9502584.
7. Dorsey, B.D., Levin, R.B., McDaniel, S.L. et al. L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem 1994, 37: 3443-51.
8. Vacca, J.P., Dorsey, B.D., Guare, J.P., Holloway, M.K., Hungate, R.W., Levin, R.B. (Merck & Co., Inc.). HIV protease inhibitors useful for the treatment of AIDS. EP 696277, US 5413999, WO 9426717.
9. Vacca, J.P., Guare, J.P., Dorsey, B.D., Holloway, M.K., Hungate, R.W. (Merck & Co., Inc.). HIV protease inhibitors in pharmaceutical combinations for the treatment of AIDS. EP 617968, WO 9422480.
10. Rossen, K., Weissman, S.A., Sager, J., Reamer, R.A., Askin, D., Volante, R.P., Reider, P.J. Asymmetric hydrogenation of tetrahydropyrazines: Synthesis of (S)-piperazine-2-tert-butylcarboxamide, an intermediate in the preparation of the HIV protease inhibitor indinavir. Tetrahedron Lett 1995, 36: 6419-22.
11. Prous, J.R. AIDS medicines. In: The Year's Drug News - Therapeutic Targets, 1995 Edition, Prous Science Publishers, Barcelona, 1995, 465-87.
12. Vacca, J.P., Dorsey, B.D., Schleif, W.A. et al. L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 1994, 91: 4096-100.
13. Condra, J.H., Blahy, O.M., Bush, B.L. et al. Mutations in HIV-1 protease residues affecting susceptibility to L-735,524. J Cell Biochem Suppl 1994, 18(Part D): Abst S 408.
14. Chen, Z., Li, Y., Schock, H.B., Hall, D., Chen, E., Kuo, L.C. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J Biol Chem 1995, 270: 21433-6.
15. Condra, J.H., Schleif, W.A., Blahy, O.M. et al. Mutations in HIV protease conferring resistance to inhibitor L-735,524. 2nd Natl Conf Hum Retroviruses Relat Infect (Jan 29-Feb 2, Washington DC) 1995, Abst 187.
16. Condra, J.H., Schleif, W.A., Blahy, O.M. et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374: 569-71.
17. Mo, H., Markowitz, M., Ho, D.D. Patterns of specific mutations in HIV-1 protease that confer resistance to a panel of protease inhibitors. 2nd Natl Conf Hum Retroviruses Relat Infect (Jan 29-Feb 2, Washington DC) 1995, Abst 188.
18. Gulnik, S.V., Suvorov, L.I., Liu, B., Yu, B., Anderson, B., Mitsuya, H., Erickson, J.W. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 1995, 34: 9282-7.
19. Tisdale, M., Myers, R.E., Maschera, B., Parry, N.R., Oliver, N.M., Blair, E.D. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995, 39: 1704-10.
20. Chen, I.-W., Vastag, K.J., Lin, J.H. High-performance liquid chromatographic determination of a potent and selective HIV protease inhibitor (L-735,524) in rat, dog and monkey plasma. J Chromatogr B-Biomed Appl 1995, 672: 111-7.
21. Woolf, E., Au, T., Haddix, H., Matuszewski, B. Determination of L-735524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching. J Chromatogr A 1995, 692: 45-52.
22. Lin, J.H., Chen, I.-W., Vastag, K.J., Ostovic, D. pH-Dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab Dispos 1995, 23: 730-5.
23. Chen, I.-W., Vastag, K., Lin, J.H. Effect of pH on oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Pharm Res 1994, 11(10, Suppl.): Abst PPDM 8368.
24. Lin, J.H., Chen, I.-W., Vastag, K. Physiological disposition and metabolism of L-735,524, a potent HIV protease inhibitor in laboratory animals. Pharm Res 1993, 10(10, Suppl.): Abst PPDM 8303.
25. Kwei, G.Y., Novak, L.B., Hettrick, L.A., Reiss, E.R., Ostovic, D., Loper, A.E., Lui, C.Y., Higgins, R.J., Chen, I.-W., Lin, J.H. Regiospecific intestinal absorption of the HIV protease inhibitor L-735,524 in beagle dogs. Pharm Res 1995, 12: 884-8.
26. Waldman, S.A., Teppler, H., Osborne, B., Bjornsson, T.D., Pomerantz, R., Woolf, E., Yeh, K., Deutsch, P., Squires, K., Saag, M. Pharmacokinetics of L-735,524, an HIV protease inhibitor. Clin Pharmacol Ther 1994, 55(2): Abst PIII-52.
27. Squires, K.E., Saag, M.S., Teppler, H., Pomerantz, R., Waldman, S., Bjornsson, T., Woolf, E., Yeh, K., Emini, E., Deutsch, P. Phase I studies of L-735,524, an HIV protease inhibitor: Pharmacokinetics, tolerability and short-term antiviral activity. Clin Res 1994, 42(2): 280A.
28. Saag, M.S., Squires, K.E., Teppler, H., Pomerantz, R., Waldman, S., Bjornsson, T., Shaw, G.M., Kappes, J., Emini, E., Deutsch, P. Clinical trials of inhibitors of the HIV-1 protease. J Cell Biochem Suppl 1994, 18(Part B): Abst J 023.
29. Chiba, M., Hensleigh, M., Nishime, J.A., Balani, S.K., Lin, J.H. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 1996, 24: 307-14.
30. Hensleigh, M., Chiba, M., Lin, J.H. Hepatic and intestinal metabolism of MK-639, an HIV protease inhibitor, in rats and human. Pharm Res 1995, 12(9, Suppl.): Abst PPDM 8190.
31. Chiba, M., Xu, X., Nishime, J., Balani, S.K., Lin, J.H. In vivo and in vitro metabolism of L-735,524 in human. Pharm Res 1994, 11(10, Suppl.): Abst PPDM 8239.
32. Balani, S.K., Arison, B.H., Mathai, L., Kauffman, L.R., Miller, R.R., Stearns, R.A., Chen, I.-W., Lin, J.H. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab Dispos 1995, 23: 266-70.
33. Deutsch, P., Teppler, H., Squires, K. et al. Antiviral activity of L-735,524, an HIV protease inhibitor, in infected patients. 34th Intersci Conf Antimicrob Agents Chemother (Oct 4-7, Orlando) 1994, Abst I59.
34. Stein, D.S., Fish, D.G., Chodakewitz, J., Emini, E., Hildebrand, C., Preston, S.L., Martineau, G.L., Drusano, G.L. A 24 week open label phase 1 evaluation of the HIV protease inhibitor L735524. 2nd Natl Conf Hum Retroviruses Relat Infect (Jan 29-Feb 2, Washington DC) 1995, Abst LB1.
35. Stein, D.S., Fish, D., Drusano, G.L. Modeling of the change in CD4 cell counts in patients before and after receiving the HIV-protease inhibitor L-735,524 (L). 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst I107.
36. Chodakewitz, J., Deutsch, P., Leavitt, R., Massari, F., Hildebrand, C., Justice, S., Makurath, M., Schleif, B., Calandra, G., Emini, E. Preliminary evaluation of the long term safety & antiviral activity exerted by Crixivan (MK-639), an oral HIV protease inhibitor. 5th Eur Conf Clin Aspects Treat HIV Infect (Sept 26-29, Copenhagen) 1995, Abst 43.
37. 3. 2nd Natl Conf Hum Retroviruses Relat Infect (Jan 29-Feb 2, Washington DC) 1995, Abst 183.
38. 3. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst I172.
39. Falloon, J., Owen, C., Kovacs, J. et al. MK-639 (Merck HIV protease inhibitor) with interleukin-2 (IL2) in HIV. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst I176.
40. Exciting results with Merck's Crixivan® could change the way doctors treat HIV disease and AIDS. HIV not detected in about 85 percent of patients taking one powerful combination with Crixivan, study shows. Merck & Co., Inc. Press Release 1996, January 29.
41. Study with Merck's AIDS drug, Crixivan®, shows significant immune system recovery and reduction in virus levels. Dramatic benefits of Merck's protease inhibitor demonstrated when taken in combination with other AIDS medications. Merck & Co., Inc. Press Release 1996, January 30.
42. AIDS virus reduced below the limit of detection in many patients taking Crixivan® in new triple combination. Preliminary late-breaking data from ongoing study shows potential benefits of Merck's protease inhibitor when taken in combination with two other AIDS medications. Merck & Co., Inc. Press Release 1996, February 1.
43. FDA grants U.S. marketing clearance for Crixivan™, new protease inhibitor for HIV/AIDS. MSD's AIDS medication receives accelerated review. Merck & Co., Inc. Press Release 1996, March 14.
44. Merck & Co., Inc. Product Fact Sheet 1996, March.
45. Spector, R., Deutsch, P.J., Nies, A. (Merck & Co., Inc.). Combination therapy for HIV infection. WO 9510281.
46. New product intros. Drug News Perspect 1996, 9: 164.
47. Vacca, J.P., Dorsey, B.D., Darke, P. et al. L-735,524, an orally bioavailable HIV-1 protease inhibitor. 9th Int Conf AIDS/4th STD World Cong (June 6-11, Berlin) 1993, Abst PO-B26-2023.
48. Emini, E.A, Vacca, J.P., Dorsey, B.D. et al. L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Antivir Res 1994, 23(Suppl. 1): Abst 4.
49. Condra, J.H., Schleif, W.A., Blahy, O.M. et al. In vivo selection by monotherapy of HIV-1 variants resistant to multiple protease inhibitors. Antivir Res 1995, 26(3): Abst 23.
50. Vacca, J.P. The development of HIV-1 protease inhibitors. 24th Natl Med Chem Symp (June 21-,25, Salt Lake City) 1994, 33.
51. Dorsey, B.D., Levin, R.B., McDaniel, S.L. et al. L735,524: The rational design of a potent and orally bioavailable HIV protease inhibitor. 206th ACS Natl Meet (Aug 22-27, Chicago) 1993, Abst MEDI 6.
52. Saag, M. New approaches to antiretroviral therapy. 34th Intersci Conf Antimicrob Agents Chemother (Oct 4-7, Orlando) 1994, 272.
53. Shafiee, A., Chen, T., Arison, B., Miller, R., Schwartz, M. HIV-protease inhibitory activity of microbially synthesized analogs of Merck's compound, MK-639. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst I126.
54. Huff, J.R., Vacca, J.P., Dorsey, B.D. et al. The design and synthesis of orally bioavailable HIV-1 protease inhibitors. J Cell Biochem Suppl 1994, 18(Part D): Abst S 037.
55. Volante, R.P. Synthesis of the orally active HIV-protease inhibitor, indinavir sulfate (MK-639). 31st Annu ACS Western Reg Meet/4th Annu San Diego Biotech Expos (Oct 18-21, San Diego) 1995, Abst 170.
56. Kwei, G.Y., Novak, L.B., Hettrick, L.A., Reiss, E.R., Ostovic, D., Loper, A.E., Chen, I.W., Lin, J.H. Absorption characteristics of the HIV protease inhibitor L-735,524 in beagle dogs. Pharm Res 1994, 11(10, Suppl.): Abst PPDM 8198.
57. Huff, J.R., Vacca, J.P., Dorsey, B.D. et al. Crixivan™: A potent inhibitor of HIV-1 protease in vivo. 211th ACS Natl Meet (March 24-28, New Orleans) 1996, Abst MEDI 255.
58. The use of indinavir reduces HIV to undetectable levels and increases quality of life in AIDS patients. Merck & Co., Inc. Press Release 1996, May 10.
59. Merck files new drug application for protease inhibitor Crixivan®. Merck & Co., Inc. Press Release 1996, January 31.